ALEC vs. PROK, VALN, ALLO, VYGR, HUMA, CCCC, EDIT, TSHA, ADPT, and ITOS
Should you be buying Alector stock or one of its competitors? The main competitors of Alector include ProKidney (PROK), Valneva (VALN), Allogene Therapeutics (ALLO), Voyager Therapeutics (VYGR), Humacyte (HUMA), C4 Therapeutics (CCCC), Editas Medicine (EDIT), Taysha Gene Therapies (TSHA), Adaptive Biotechnologies (ADPT), and iTeos Therapeutics (ITOS). These companies are all part of the "biological products, except diagnostic" industry.
Alector (NASDAQ:ALEC) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and community ranking.
ProKidney has a net margin of 0.00% compared to Alector's net margin of -125.11%. ProKidney's return on equity of 0.00% beat Alector's return on equity.
Alector has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
85.8% of Alector shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 14.0% of Alector shares are held by company insiders. Comparatively, 45.0% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Alector presently has a consensus target price of $14.00, suggesting a potential upside of 159.74%. ProKidney has a consensus target price of $9.50, suggesting a potential upside of 208.44%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than Alector.
ProKidney has lower revenue, but higher earnings than Alector. ProKidney is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
Alector received 140 more outperform votes than ProKidney when rated by MarketBeat users. However, 66.67% of users gave ProKidney an outperform vote while only 60.58% of users gave Alector an outperform vote.
In the previous week, Alector had 6 more articles in the media than ProKidney. MarketBeat recorded 14 mentions for Alector and 8 mentions for ProKidney. ProKidney's average media sentiment score of 0.78 beat Alector's score of 0.41 indicating that ProKidney is being referred to more favorably in the news media.
Summary
ProKidney beats Alector on 9 of the 17 factors compared between the two stocks.
Get Alector News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
